ging of amphetamine-induced dopamine release in drug-free schizophrenic subjects". Proc. Natl. Acad. Sci. U.S.A. 93 (17): 9235–40. doi:10.1073/pnas.93.17.9235. PMC 38625. PMID 8799184. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)↑ Jones HM, Pilowsky LS (2002). "Dopamine and antipsychotic drug action revisited". British Journal of Psychiatry. 181: 271–275. doi:10.1192/bjp.181.4.271. PMID 12356650.↑ Konradi C, Heckers S (2003). "Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment". Pharmacology and Therapeutics. 97 (2): 153–79. doi:10.1016/S0163-7258(02)00328-5. PMID 12559388.↑ Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). "Effects of ketamine in normal and schizophrenic volunteers". Neuropsychopharmacology. 25 (4): 455–67. doi:10.1016/S0893-133X(01)00243-3. PMID 11557159.{{cite journal}}:  CS1 maint: multiple names: authors list (link)↑ Coyle JT, 